Methodologic Issues in the Validation of Putative Biomarkers and Surrogate Endpoints in Treatment Evaluation for Systemic Lupus Erythematosus

Endocrine, Metabolic and Immune Disorders - Drug Targets - United Arab Emirates
doi 10.2174/187153009787582388

Related search